Home › Rheumatoid Arthritis › New York › The Bronx
Rheumatoid Arthritis clinical trials in The Bronx, NY
3 studies for Rheumatoid Arthritis are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RecruitingPhase 2
- Northwell Health Physician Partners Rheumatology At Great Neck /ID# 275621, Great Neck · 8 mi away
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RecruitingPhase 2
- Equity Medical, The Bronx
- Equity Medical, The Bronx
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RecruitingPhase 2
- Northwell Health, Great Neck · 8 mi away
About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, and stiffness in your joints. Your risk increases as you become an older adult.
More about Rheumatoid Arthritis on MedlinePlus
Rheumatoid Arthritis trials in other cities
- Houston, TX11 studies
- New York City, NY10 studies
- Durham, NC8 studies
- Altoona, PA7 studies
- Aurora, CO7 studies
- Dallas, TX7 studies
- Boston, MA7 studies
- San Diego, CA6 studies
- Plantation, FL6 studies
- Chicago, IL6 studies
- Miami, FL5 studies
- West Palm Beach, FL5 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Prostate Cancer11 studies
- Heart Failure11 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Asthma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.